PharmGKB summary: very important pharmacogene information for SLC22A1

Affiliations

¹ aDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco Departments of bGenetics cBioengineering, Stanford University, Palo Alto, California, USA.

Srijib Goswami et al. Pharmacogenet Genomics. 2014 Jun.

. 2014 Jun;24(6):324-8.

doi: 10.1097/FPC.0000000000000048.

¹ aDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco Departments of bGenetics cBioengineering, Stanford University, Palo Alto, California, USA.

No abstract available

References

1. Hayer M, Bonisch H, Bruss M. Molecular cloning, functional characterization and genomic organization of four alternatively spliced isoforms of the human organic cation transporter 1 (hOCT1/SLC22A1) Ann Hum Genet. 1999;63(Pt 6):473–482. - PubMed
1. Koepsell H. The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med. 2013;4:413–435. - PubMed
1. Shu Y, Leabman MK, Feng B, Mangravite LM. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA. 2003;100:5902–5907. - PMC - PubMed
1. Tzvetkov MV, Saadatmand AR, Lötsch J, Tegeder I, Stingl JC, Brockmöller J. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther. 2009;90:143–150. - PubMed
1. Saborowski M. Human OCT1 gene is transactivated by HNF4A. J Pharmacol Exp Ther. 2006;317:778–785. - PubMed